Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Johnson & Johnson (NYSE:JNJ)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
Recent Events
Aug 15Price hit new 52-week high ($57.60)
Upcoming Events
Sep 11Dividend payment of $0.18
Location
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Phone: (732) 524-0400
Fax: (732) 214-0332
Employees (last reported count): 100,942
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Major Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Subsidiaries
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·Dow Industrials
 ·S&P 500
Ownership
·Insider and 5%+ Owners: 1%
·Over the last 6 months:
 · 4 insider sells; 79.0K shares
  (0.3% of insider shares)
·Institutional: 60% (60% of float)
(2,861 institutions)
·Net Inst. Buying: 217.7M shares (+10.46%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world. Historically, Johnson & Johnson's primary interest was in products related to human health and well being. Johnson & Johnson's worldwide business is divided into three segments: Consumer, Pharmaceutical and Professional. In June 2001, the Company merged with ALZA Corporation. Under the terms of the merger, ALZA Corporation will retain its name and survive as a direct, wholly owned subsidiary of Johnson & Johnson. ALZA Corporation is a research-based pharmaceutical company that offers drug delivery technologies. ALZA applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many pharmaceutical companies. ALZA's sales and marketing efforts are focused on urology, oncology and central nervous system products.
More from Market Guide: Expanded Business Description

Financial Summary
Johnson and Johnson is a manufacturer of heatlh care products serving the consumer, pharmaceutical and professional markets. For the six months ended 6/30/01, revenues rose 8% to $16.36 billion. Net income rose 13% to $3.03 billion. Revenues reflect a strong performance of PROCRIT/EPREX and RISPERDAL and an increase in sales of skin care product lines. Net income reflects improved profit margin and decreased SG&A expenses as a percentage of sales.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Ralph Larsen, 62
Chairman, CEO
$4.7M$2.9M
James Lenehan, 52
Vice Chairman Medical Devices & Diagnostics Group
1.8M604K
William Weldon, 52
Vice Chairman
1.7M684K
Robert Wilson, 60
Sr. Vice Chairman
3.5M4.0M
Robert Daretta, 54
VP-Fin.
--  --  
Dollar amounts are as of 3-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:JNJAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-Mar-2001
$40.25 
Recent Price$52.71 
52-Week High
on 15-Aug-2001
$57.60 
Beta0.58 
Daily Volume (3-month avg)7.35M
Daily Volume (10-day avg)6.07M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+13.8%
52-Week Change
relative to S&P500
+52.7%
Share-Related Items
Market Capitalization$164.4B
Shares Outstanding3.12B
Float3.09B
Dividends & Splits
Annual Dividend (indicated)$0.72 
Dividend Yield1.37%
Last Split: 2 for 1 on 13-June-2001
Per-Share Data
Book Value (mrq*)$7.49 
Earnings (ttm)$1.73 
Earnings (mrq)$0.48 
Sales (ttm)$10.02 
Cash (mrq*)$2.48 
Valuation Ratios
Price/Book (mrq*)7.04 
Price/Earnings (ttm)30.52 
Price/Sales (ttm)5.26 
Income Statements
Sales (ttm)$31.2B
EBITDA (ttm*)$8.74B
Income available to common (ttm)$5.34B
Profitability
Profit Margin (ttm)17.1%
Operating Margin (ttm)23.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
1-July-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)15.62%
Return on Equity (ttm)25.79%
Financial Strength
Current Ratio (mrq*)2.48 
Debt/Equity (mrq*)0.15 
Total Cash (mrq)$7.52B
Short Interest
As of 8-Aug-2001
Shares Short41.5M
Percent of Float1.3%
Shares Short
(Prior Month)
50.1M
Short Ratio5.61 
Daily Volume7.40M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 1-July-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.